For help on how to get the results you want, see our search tips.
3 results
Medicine
Maximum residue limits Remove Maximum residue limits filter
Withdrawn applications Remove Withdrawn applications filter
Referrals Remove Referrals filter
Categories
Human Remove Human filter
Referral type
Article 6(12) referrals (prior to January 2010) Remove Article 6(12) referrals (prior to January 2010) filter
Article 107i procedures Remove Article 107i procedures filter
Article 20 procedures Remove Article 20 procedures filter
Medicine type
Orphan medicine Remove Orphan medicine filter
Exceptional circumstances Remove Exceptional circumstances filter
Additional monitoring Remove Additional monitoring filter
Accelerated assessment Remove Accelerated assessment filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Referral safety status
Yes Remove Yes filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
-
List item
Referral: Janus kinase inhibitors (JAKi) (updated)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Picato
ingenol mebutate, associated names: Picato, Article 20 procedures
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 06/07/2020, Last updated: 16/11/2020 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020